News Releases

Date Title and Summary Additional Formats
Toggle Summary 'Clinical Cancer Research' Article States Tarvacin(TM) Equivalent Inhibits Tumor Growth by up to 90% in Multiple Tumor Models
'Clinical Cancer Research' Article States Tarvacin(TM) Equivalent Inhibits Tumor Growth by up to 90n Multiple Tumor Models Data Support Development of Tarvacin™ as Broad Spectrum Anti-Cancer Agent TUSTIN, Calif., March 7, 2005 /PRNewswire-FirstCall via COMTEX/ -- Peregrine Pharmaceuticals, Inc.
View HTML
Toggle Summary Affitech AS and Peregrine Pharmaceuticals Announce Research Milestone Achievement by Affitech
Affitech AS and Peregrine Pharmaceuticals Announce Research Milestone Achievement by Affitech TUSTIN, Calif., and OSLO, Norway, June 24 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) and Affitech AS today announced that they have achieved the first research milestone in
View HTML
Toggle Summary ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer
-- Career Development Award to Study Biology of Bavituximab and Chemotherapy in Lung Cancer Awarded to Dr. David Gerber of UT Southwestern Medical Center - -- New Study Complements Ongoing Bavituximab Plus Carboplatin/Paclitaxel Phase II NSCLC Trial that has Shown Promising Preliminary Results -
View HTML
Toggle Summary AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial
- Global, Randomized Phase II Trial to Evaluate Immunotherapy Combination of Peregrine's PS-Targeting Bavituximab and AstraZeneca's PD-L1 Inhibitor Durvalumab (MEDI4736) in Previously Treated NSCLC -
View HTML
Toggle Summary AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial
Collaboration to Focus on Cancer Immunotherapy Combination of Peregrine's PS-Targeting Bavituximab and AstraZeneca's PD-L1 Inhibitor MEDI4736
View HTML
Toggle Summary Avanir And Peregrine Execute Commercial License Agreement For Anti-Cancer Antibody
Avanir And Peregrine Execute Commercial License Agreement For Anti-Cancer Antibody SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- Avanir Pharmaceuticals (Amex: AVN) announced today that a Commercial License Agreement with Peregrine Pharmaceuticals, Inc.
View HTML
Toggle Summary Avid Bioservices Added to Russell 3000® Index and Russell 2000® Index
TUSTIN, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology
View HTML
Toggle Summary Avid Bioservices and Bioreliance Team Up To Provide Eukaryotic Cell Banking Services to the Biopharmaceutical Industry
Avid Bioservices and Bioreliance Team Up To Provide Eukaryotic Cell Banking Services to the Biopharmaceutical Industry Tustin, CA -September 20, 2005 - Avid Bioservices, Inc., a subsidiary of Peregrine Pharmaceuticals Inc. (PPHM), announced today that it has teamed up with BioReliance, Inc., a
View HTML
Toggle Summary Avid Bioservices and Halozyme Therapeutics Expand Commercial Supply Relationship with New Manufacturing Agreements
Designated a Preferred Supplier for Halozyme
View HTML
Toggle Summary Avid Bioservices and Halozyme Therapeutics Extend Commercial Manufacturing Agreement
Avid Bioservices and Halozyme Therapeutics Extend Commercial Manufacturing Agreement - Extended Terms May Include Up to 20 cGMP Runs per Year - TUSTIN, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc.
View HTML